REGENXBIO (NASDAQ:RGNX) Vs. DNLI, VIR, ABCM, FATE, KOD, SWTX, TWST, BCRX, RLAY, and IOVA
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.
REGENXBIO vs.
Vir Biotechnology (NASDAQ:VIR) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
REGENXBIO received 382 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 68.86% of users gave REGENXBIO an outperform vote while only 51.61% of users gave Vir Biotechnology an outperform vote.
REGENXBIO has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Vir Biotechnology has a beta of -1.54, suggesting that its stock price is 254% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
Vir Biotechnology presently has a consensus price target of $97.50, suggesting a potential upside of 210.91%. REGENXBIO has a consensus price target of $54.00, suggesting a potential upside of 106.82%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than REGENXBIO.
Vir Biotechnology has a net margin of -35.98% compared to REGENXBIO's net margin of -228.08%. Vir Biotechnology's return on equity of -13.73% beat REGENXBIO's return on equity.
In the previous week, Vir Biotechnology had 7 more articles in the media than REGENXBIO. MarketBeat recorded 11 mentions for Vir Biotechnology and 4 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.27 beat Vir Biotechnology's score of -0.01 indicating that REGENXBIO is being referred to more favorably in the news media.
56.6% of Vir Biotechnology shares are held by institutional investors. Comparatively, 78.5% of REGENXBIO shares are held by institutional investors. 30.9% of Vir Biotechnology shares are held by insiders. Comparatively, 12.4% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
REGENXBIO beats Vir Biotechnology on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO (NASDAQ:RGNX) vs. Its Competitors
REGENXBIO Competitors List
